References:

[1] Patrick GL. An Introduction to Medicinal Chemistry. UCL Lect Notes 2009;40:752.

[2] Society AC. Cancer Treatment. Cancer Treat Surviv Facts Fig 2013:44.

[3] Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (80-) 1999;286:531–7.

[4] Torpy JM. Cancer: The Basics. JAMA J Am Med Assoc 2010;304:1628.

[5] Herbst RS, Heymach J V, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367–80.

[6] American Cancer Society. Cancer Facts & Figures 2016. Cancer Facts Fig 2016 2016:1–9.

[7] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7–30.

[8] Takiar R, Nadayil D, Nandakumar A. Projections of number of cancer cases in India (2010-2020) by cancer groups. Asian Pacific J Cancer Prev 2010;11:1045–9.

[9] BioSpectrum. 1,300 Indians die of cancer every day: ICMR. Biospectrum 2015.

[10] CRUK. Types of cells and cancer. CancerHelp UK 2013. http://www.cancerresearchuk.org/cancer-help/about-cancer/what-is-cancer/cells/types-of-cells-and-cancer.

[11] Cancer Research UK. Surgery to treat cancer. Cancer Treat 2014.

[12] Therapy R, Cdks B. The Science Behind Radiation Therapy. Am Cancer Soc 2014:15.

[13] Couzin-Frankel J. Cancer Immunotherapy. Science (80-) 2013;342:1432–3.

[14] Stokes Z, Chan S. Principles of cancer treatment by hormone therapy. Surgery 2009;27:165–8.

[15] Beck B, Blanpain C. Unravelling cancer stem cell potential. Nat Rev Cancer 2013;13:727–38.

[16] Friedman A a., Letai A, Fisher DE, Flaherty KT. Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer 2015;15:747–56.

[17] Melero I, Berman DM, Aznar MA, Korman AJ, Gracia JLP, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer 2015;15:457–72.

[18] World Health Organization, Cancer Research UK. World cancer factsheet. World Heal Organ 2014;2012:4.

[19] Yarden Y, Shilo B-Z. SnapShot: EGFR signaling pathway. Cell 2007;131:1018.

[20] Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37 Suppl 4:S9–15.

[21] Kandasamy K, Mohan SS, Raju R, Keerthikumar S, Kumar GSS, Venugopal AK, et al. NetPath: a public resource of curated signal transduction pathways. Genome Biol 2010;11:R3.

[22] Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2–16.

[23] Olayioye M a, Neve RM, Lane H a, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159–67.

[24] Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A, Paradiso A. The complexity of targeting EGFR signalling in cancer: From expression to turnover. Biochim Biophys Acta - Rev Cancer 2006;1766:120–39.

[25] Batzer AG, Rotin D, Ureña JM, Skolnik EY, Schlessinger J. Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol Cell Biol 1994;14:5192–201.

[26] Dhillon a S, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007;26:3279–90.

[27] Anjum R, Blenis J. The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 2008;9:747–58.

[28] Li J. PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer. Science (80-) 1997;275:1943–7.

[29] Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004;22:2954–63.

[30] Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress. Mol Cell 2010;40:310–22.

[31] Carroll B, Maetzel D, Maddocks ODK, Otten G, Ratcliff M, Smith GR, et al. Control of TSC2-Rheb signaling axis by arginine regulates mTORC1 activity. Elife 2016;5.

[32] Yano S, Kondo K, Yamaguchi M, Richmond G, Hutchison M, Wakeling A, et al. Distribution and Function of EGFR in Human Tissue and the Effect of EGFR Tyrosine Kinase Inhibition. Anticancer Res 2003;23:3639–50.

[33] Albanell J, Gascón P. Small molecules with EGFR-TK inhibitor activity. Curr Drug Targets 2005;6:259–74.

[34] Chong CR, Jänne P a. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 2013;19:1389–400.

[35] Antonicelli A, Cafarotti S, Indini A, Galli A, Russo A, Cesario A, et al. Egfr-targeted therapy for non-small cell lun cancer: Focus on EGFR oncogenic mutation. Int J Med Sci 2013;10:320–30.

[36] Spano JP, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R, et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 2005;16:102–8.

[37] Oliveira-Cunha M, Newman WG, Siriwardena AK. Epidermal growth factor receptor in pancreatic cancer. Cancers (Basel) 2011;3:1513–26.

[38] Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat 2012;136:331–45.

[39] Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006;24:2666–72.

[40] Chouaid C, Atsou K, Hejblum G, Vergnenegre A. Economics of treatments for non-small cell lung cancer. Pharmacoeconomics 2009;27:113–25.

[41] Doss GPC, Rajith B, Chakraborty C, NagaSundaram N, Ali SK, Zhu H. Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors. Sci Rep 2014;4:5868.

[42] Steuer CE, Khuri FR, Ramalingam SS. The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. Cancer 2015;121:E1–6.

[43] Piotrowska Z, Niederst MJ, Karlovich CA, Wakelee HA, Neal JW, Mino-Kenudson M, et al.

Heterogeneity underlies the emergence of EGFR^{T790}wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov 2015;5:713–23.

[44] Nguyen K-SH, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009;10:281–9.

[45] Yasuda H, Park E, Yun C-H, Sng NJ, Lucena-Araujo AR, Yeo W-L, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med 2013;5:216ra177.

[46] Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006;12:6494–501.

[47] Onitsuka T, Uramoto H, Nose N, Takenoyama M, Hanagiri T, Sugio K, et al. Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer 2010;68:198–203.

[48] Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 2007;4:1669–80.

[49] Song HN, Jung KS, Yoo KH, Cho J, Lee JY, Lim SH, et al. Acquired C797S mutation upon treatment with a T790M-specific third-generation EGFR inhibitor (HM61713) in non-small cell lung cancer. J Thorac Oncol 2016;11:e45–7.

[50] Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16:15–31.

[51] Wu P, Nielsen TE, Clausen MH. Small-molecule kinase inhibitors: An analysis of FDA-approved drugs. Drug Discov Today 2016;21:5–10.

[52] Yaish P, Gazit a, Gilon C, Levitzki a. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science (80-) 1988;242:933–5.

[53] Finlay MR V, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, et al. Discovery of a

potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem 2014;57:8249–67.

[54] Zhang L, Yang Y, Zhou H, Zheng Q, Li Y, Zheng S, et al. Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors. Eur J Med Chem 2015;102:445–63.

[55] Hu S, Xie G, Zhang DX, Davis C, Long W, Hu Y, et al. Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors. Bioorganic Med Chem Lett 2012;22:6301–5.

[56] Cheng H, Nair SK, Murray BW, Almaden C, Bailey S, Baxi S, et al. Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants. J Med Chem 2016;59:2005–24.

[57] Sequist L V, Waltman B a, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.

[58] Walter AO, Sjin RTT, Haringsma HJ, Sun J, Ohashi K, Lee K, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M mediated resistance in NSCLC. Cancer Discov 2013;3:1404–15.

[59] Minguet J, Smith KH, Bramlage P. Targeted therapies for treatment of non-small cell lung cancer - Recent advances and future perspectives. Int J Cancer 2016;138:2549–61.

[60] Sequist L V, Soria J-C, Goldman JW, Wakelee H a, Gadgeel SM, Varga A, et al. Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med 2015;372:1700–9.

[61] Jia Y, Juarez J, Manuia M, Lelais G, Kasibhatla S, Long O, et al. Abstract 1734: In vitro characterization of EGF816, a third-generation mutant-selective EGFR inhibitor. Cancer Res 2014;74:1734–1734.

[62] Kasibhatla S, Li J, Tompkins C, Vaillancourt M-T, Anderson J, Pferdekamper AC, et al. Abstract 1733: EGF816, a novel covalent inhibitor of mutant-selective epidermal growth factor receptor, overcomes T790M-mediated resistance in NSCLC. Cancer Res

2014;74:1733–1733.

[63] Sakagami H, Konagai S, Yamamoto H, Tanaka H, Matsuya T, Mori M, et al. ASP8273, a novel mutant-selective irreversible EGFR inhibitor, inhibits growth of non-small cell lung cancer (NSCLC) cells with EGFR activating and T790M resistance mutations. Cancer Res 2014;74:#Abstr 1728.

[64] Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009;462:1070–4.

[65] Lee et al KO. Discovery of HM61713 as an orally available and mutant EGFR selective inhibitor. Cancer Res 2014;74:#Abstr LB-100.

[66] Ercan D, Choi HG, Yun C-H, Capelletti M, Xie T, Eck MJ, et al. EGFR mutations and resistance to Irreversible pyrimidine based EGFR inhibitors. Clin Cancer Res 2015:1078-0432.CCR-14-2789-.

[67] Lee HJ, Schaefer G, Heffron TP, Shao L, Ye X, Sideris S, et al. Noncovalent wild-type-sparing inhibitors of EGFR T790M. Cancer Discov 2013;3:168–81.

[68] Cheng H, Nair SK, Murray BW, Almaden C, Bailey S, Baxi S, et al. Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants. J Med Chem 2016;59:2005–24.

[69] Belani CP, Nemunaitis JJ, Chachoua A, Eisenberg PD, Raez LE, Cuevas JD, et al. Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer. Cancer Biol Ther 2013;14:557–63.

[70] Kaspersen SJ, Sørum C, Willassen V, Fuglseth E, Kjøbli E, Bjørkøy G, et al. Synthesis and in vitro EGFR (ErbB1) tyrosine kinase inhibitory activity of 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines. Eur J Med Chem 2011;46:6002–14.

[71] Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 2015;21:560–2.

[72] Hu M, Ye W, Li J, Zhong G, He G, Xu Q, et al. Synthesis and Evaluation of Salicylanilide Derivatives as Potential Epidermal Growth Factor Receptor Inhibitors. Chem Biol Drug Des 2014:1–10.

[73] Zhang Q, Diao Y, Wang F, Fu Y, Tang F, You Q, et al. Design and discovery of 4-anilinoquinazoline ureas as multikinase inhibitors targeting BRAF, VEGFR-2 and EGFR. Medchemcomm 2013;4:979.

[74] Barbosa MLDC, Lima LM, Tesch R, Sant'Anna CMR, Totzke F, Kubbutat MHG, et al. Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors. Eur J Med Chem 2014;71:1–14.

[75] Bugge S, Kaspersen SJ, Larsen S, Nonstad U, Bj??rk??y G, Sundby E, et al. Structure-activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor. Eur J Med Chem 2014;75:354–74.

[76] Ismail RSM, Ismail NSM, abuserii S, Abou El Ella DA. Recent advances in 4-aminoquinazoline based scaffold derivatives targeting EGFR kinases as anticancer agents. Futur J Pharm Sci 2016.

[77] Yang M, Pickard AJ, Qiao X, Gueble MJ, Day CS, Kucera GL, et al. Synthesis, reactivity, and biological activity of gold(i) complexes modified with thiourea-functionalized tyrosine kinase inhibitors. Inorg Chem 2015;54:3316–24.

[78] American Type Culture Collection. MTT Cell Proliferation Assay Instruction Guide. Components 2011;6597:1–6.

[79] Chitkara D, Singh S, Kumar V, Danquah M, Behrman SW, Kumar N, et al. Micellar delivery of cyclopamine and gefitinib for treating pancreatic cancer. Mol Pharm 2012;9:2350–7.

[80] Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy. J Med Chem 2004;47:1739–49.

[81] ChemAxon. Marvin Sketch. Https://www.chemaxon.com/products/marvin/ 2013.

[82] Shelley JC, Cholleti A, Frye LL, Greenwood JR, Timlin MR, Uchimaya M. Epik: A software program for pKa prediction and protonation state generation for drug-like molecules. J Comput Aided Mol Des 2007;21:681–91.

[83] Fernandes J, Gattass CR. Topological polar surface area defines substrate transport by multidrug resistance associated protein 1 (MRP1/ABCC1). J Med Chem 2009;52:1214–8.

[84] Pollastri MP. Overview on the rule of five. Curr Protoc Pharmacol 2010.

[85] Sander T, Freyss J, Von Korff M, Reich JR, Rufener C. OSIRIS, an entirely in-house developed drug discovery informatics system. J Chem Inf Model 2009;49:232–46.

[86] Cheng F, Li W, Zhou Y, Shen J, Wu Z, Liu G, et al. AdmetSAR: A comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model 2012;52:3099–105.

[87] Meinl T, Ostermann C, Berthold MR. Maximum-score diversity selection for early drug discovery. J Chem Inf Model 2011;51:237–47.

[88] Verdonk ML, Giangreco I, Hall RJ, Korb O, Mortenson PN, Murray CW. Docking performance of fragments and druglike compounds. J Med Chem 2011;54:5422–31.

[89] Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, et al. Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity. Cancer Cell 2007;11:217–27.

[90] Yurttaş L, Demirayak Ş, Ilgin S, Atli Ö. In vitro antitumor activity evaluation of some 1,2,4-triazine derivatives bearing piperazine amide moiety against breast cancer cells. Bioorganic Med Chem 2014;22:6313–23.

[91] Promega. ADP-Glo ^{TM} Kinase Assay. Luminescence 2009:1–21.